Condensed Consolidated Statements of Stockholder Equity (Deficit) (Unaudited) - USD ($) $ in Millions		Total		Total Stockholder Equity (Deficit)		Common Stock		Capital Surplus		(Accumulated Deficit) Retained Earnings		Treasury Stock		Cumulative Translation Adjustment		Defined Benefit Postretirement Plans		Cash Flow Hedging Derivative		Non-Controlling Interest
Pension adjustments, tax benefit (expense)		$ 0.1
Change in cumulative translation adjustment, tax expense (benefit)		(0.2)
Derivative financial instrument, tax expense (benefit)		(0.3)
Balance at beginning of period at Dec. 31, 2019	[1]	1,577.3		$ 1,519.1		$ 0.0		$ 2,116.8		$ (577.4)		$ 0.0		$ 4.8		$ (24.0)		$ (1.1)		$ 58.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		74.3	[2]	73.9						73.9										0.4
Accretion - Series A Preferred Stock	[3]	(1.0)		(1.0)				(1.0)
Equity-based compensation plans		3.7		3.7				3.7
Pension adjustments, net of tax expense (benefit)		(0.1)		(0.1)												(0.1)
Change in cumulative translation adjustment, net of tax expense (benefit)		(25.6)	[4],[5]	(24.3)										(24.3)						(1.3)
Derivative financial instruments, net of tax expense (benefit)		(1.0)	[4],[6]	(1.0)														(1.0)
Preferred dividend	[3]	(32.0)		(32.0)				(32.0)
Payment to non-controlling interest		(0.2)																		(0.2)
Balance at end of period at Mar. 31, 2020	[1]	1,595.4		1,538.3		0.0		2,087.5		(503.5)		0.0		(19.5)		(24.1)		(2.1)		57.1
Pension adjustments, tax benefit (expense)		(0.1)
Change in cumulative translation adjustment, tax expense (benefit)		1.1
Derivative financial instrument, tax expense (benefit)		(0.1)
Balance at beginning of period at Dec. 31, 2020		3,583.9	[7]	3,525.6	[1]	0.0	[1]	4,310.1	[1]	(693.9)	[1]	0.0	[1]	30.1	[1]	(120.3)	[1]	(0.4)	[1]	58.3	[1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		(23.3)		(25.0)						(25.0)										1.7
Shares issued for Bisnode acquisition		158.9		158.9				158.9
Equity-based compensation plans		5.9		5.9				6.2				(0.3)
Pension adjustments, net of tax expense (benefit)		0.4		0.4												0.4
Change in cumulative translation adjustment, net of tax expense (benefit)		(49.3)	[5]	(50.0)										(50.0)						0.7
Derivative financial instruments, net of tax expense (benefit)		1.8	[6]	1.8														1.8
Payment to non-controlling interest		(0.1)																		(0.1)
Balance at end of period at Mar. 31, 2021		$ 3,678.2		$ 3,617.6		$ 0.0		$ 4,475.2		$ (718.9)		$ (0.3)		$ (19.9)		$ (119.9)		$ 1.4		$ 60.6

[1] See discussion in Note 1 - Basis of Presentation for further detail regarding the elimination of the International lag reporting.

[2] See discussion in Note 1 - Basis of Presentation for further detail regarding the elimination of the International lag reporting.

[3] Related to Series A Preferred Stock which was fully redeemed in July 2020. See detail discussion in the consolidated financial statements for the year ended December 31, 2020, included in our Annual Report on Form 10-K and filed with the Securities and Exchange Commission ("SEC") on February 25, 2021.

[4] See discussion in Note 1 - Basis of Presentation for further detail regarding the elimination of the International lag reporting.

[5] Tax Expense (Benefit) of $1.1 million and $(0.2) million for the three months ended March 31, 2021 and 2020, respectively.

[6] Tax Expense (Benefit) of $(0.1) million and $(0.3) million for the three months ended March 31, 2021 and 2020, respectively.

[7] See discussion in Note 1 - Basis of Presentation for further detail regarding the elimination of the International lag reporting.